Skip to Main Content
Skip Nav Destination

Another Win for Pembrolizumab

June 17, 2024

The FDA has approved pembrolizumab (Keytruda; Merck) for another indication: When given with a regimen of carboplatin and paclitaxel, it may be used to treat primary advanced or recurrent endometrial carcinoma. The PD-1 inhibitor was evaluated in the KEYNOTE-868/NRG-GY018 trial, in which patients were assigned to one of two cohorts based on mismatch repair status—222 patients enrolled in the mismatch repair deficient (dMMR) group and 558 in the mismatch repair proficient (pMMR) group. Patients in each group received either the pembrolizumab regimen or a placebo with paclitaxel and carboplatin. All the patients who received pembrolizumab had longer progression-free survival (PFS) than the patients who received the placebo. In the dMMR cohort, the median PFS was not reached and 6.5 months, respectively; in the pMMR group, the median PFS was 11.1 months and 8.5 months, respectively. The drug is approved for dozens of indications in about 20 cancer types.

 

Close Modal

or Create an Account

Close Modal
Close Modal